Fig. 1.
Fig. 1. (Lower part) Dosages of hydroxyurea in both treatment arms during follow-up. Patients at risk are indicated. (Upper part) Dosage of IFN-α2b during follow-up. Patients at risk are indicated.

(Lower part) Dosages of hydroxyurea in both treatment arms during follow-up. Patients at risk are indicated. (Upper part) Dosage of IFN-α2b during follow-up. Patients at risk are indicated.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal